Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 7/20 | 0.52 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7411076 | 0.87 | KMT2A (0.63) | KMT2AGAAALDH1A1FFAR1NPSR1 | |
| SCHEMBL1464359 | 0.87 | KMT2A (0.73) | KMT2AGAAALDH1A1NPSR1POLB | |
| SCHEMBL7412217 | 0.85 | KMT2A (0.64) | KMT2AGAAALDH1A1NPSR1POLB | |
| SCHEMBL8249922 | 0.82 | KMT2A (0.71) | KMT2AGAAALDH1A1FFAR1NPSR1 | |
| SCHEMBL21991755 | 0.81 | MAOB (0.60) | GAAMAOAMAOBFFAR1NR4A2 | |
| SCHEMBL21992641 | 0.79 | MAOB (0.57) | KMT2AMAOAMAOBFFAR1NR4A2 | |
| SCHEMBL21991753 | 0.79 | MAOB (0.60) | ALDH1A1MAOAMAOBFFAR1NR4A2 | |
| SCHEMBL7408448 | 0.79 | KMT2A (0.66) | KMT2AGAAALDH1A1NPSR1POLB | |
| SCHEMBL7415493 | 0.78 | ATM (0.50) | KMT2AGAAALDH1A1NPSR1NPC1 | |
| SCHEMBL11230795 | 0.78 | KMT2A (0.73) | KMT2AGAAALDH1A1NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1213021-C | N-hydroxy-2- (alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl) -3-substituted alkanes as matrix metalloproteinase inhibitors | WYETH HOLDING CO (US) | 2005-08-03 | — | — | CN | disclosed |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-12-12 | — | — | US | disclosed |
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-03-14 | — | — | US | disclosed |
| US-6331563-B1 | LOW MOLECULAR WEIGHT, NON-PEPTIDE INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR-ALPHA CONVERTING ENZYME; TREATING ARTHRITIS, TUMOR METASTASIS, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, INSULIN RESISTANCE | WYETH HOLDINGS CORPORATION | 2001-12-18 | — | — | US | disclosed |
| US-6288086-B1 | COMPOUNDS SUCH AS 1-METHYL-4-(4-BUTOXY-BENZENESULFONYL) -PIPERIDINE-4-CARBOXYLIC ACID HYDROXYAMIDE USED TO TREAT ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, ETC.; LOW MOLECULAR WEIGHT AND NON-PEPTIDAL | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| CN-1291183-A | N-hydroxy-2- (alkyl, aryl or heteroaryl sulfanyl, sulfinyl or sulfonyl) -3 substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID CO (US) | 2001-04-11 | — | — | CN | disclosed |
| US-6197791-B1 | ANTIARTHRITIC AGENTS; WOUND HEALING AGENTS; ANTITUMOR AGENTS | AMERICAN CYANAMID COMPANY | 2001-03-06 | — | — | US | disclosed |
| EP-1054858-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032186-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | KMT2A 3176/4885GAA 378/4885ALDH1A1 2575/4885 |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | KMT2A 3126/4885GAA 330/4885ALDH1A1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.